Corneal collagen crosslinking in progressive keratoconus: Multicenter results from the French National Reference Center for Keratoconus

详细信息    查看全文

• 作者：Dalal Asri MD ; David Touboul MD  ; ;   ; ^{toubould@gmail.com} ; Pierre Fournié ; MD ; Florence Malet MD ; Caroline Garra ; Anne Gallois ; Franç ; ois Malecaze MD ; Joseph Colin MD
• 刊名：Journal of Cataract and Refractive Surgery
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：37
• 期：12
• 页码：2137-2143
• 全文大小：235 K

文摘

Purpose

To report refractive, topographic, and biomechanical outcomes, efficiency, and safety of corneal collagen crosslinking (CXL) 1, 3, 6, and 12 months after treatment.

Setting

National Reference Centre for Keratoconus, Bordeaux and Toulouse, France.

Design

Case series.

Methods

This retrospective uncontrolled double-center study comprised eyes with progressive keratoconus. Uncorrected distance visual acuity, corrected distance visual acuity (CDVA), corneal pachymetry, endothelial cell count, and corneal hysteresis and corneal resistance factor were evaluated at baseline and at 1, 3, 6, and 12 months.

Results

One hundred forty-two eyes were enrolled in the study. At 6 months, the CDVA had stabilized in 53 eyes (48.1 % ), improved in 36 eyes (32.7 % ), and decreased in 18 eyes (16.3 % ). At 12 months, the CDVA had stabilized in 31 eyes (47.6 % ), improved in 26 eyes (40.0 % ), and decreased in 8 eyes (12 % ). At 6 months, keratoconus progression had stopped in 51 eyes (49.03 % ) and the maximum keratometry (K) value had decreased by more than 1.0 diopter (D) in 37 eyes (35.5 % ); it continued to progress in 16 eyes (15.3 % ). At 12 months, keratoconus progression had stopped in 42 eyes (68.8 % ) and the maximum K value had decreased by more than 2.0 D in 13 eyes (21.3 % ). The complication rate with loss of vision was 3.5 % .

Conclusions

Ultraviolet-A light associated with riboflavin CXL is an efficient procedure to stabilize and improve progressive keratoconus. The results reinforce previous studies highlighting the efficacy and safety of the procedure. A large prospective randomized clinical trial is needed.

Financial Disclosure

No author has a financial or proprietary interest in any material or method mentioned.